Diabetes drugs may be useful for Alzheimer's, mice research finds
Conclusion
Both Alzheimer's disease and diabetes seem to have become more common in recent years, causing illness and putting strain on the health service. News that the two illnesses may have a common cause raises hopes that drugs which help with one disease may also be of use in treating another.
Trials of a diabetes drug on people with Alzheimer's disease are reported to be underway, although no results have been published yet. This study, suggesting a mechanism which may be involved in the early stages of both diseases, may increase the likelihood that common treatments will be useful.
The study's main limitation is th...
Source: NHS News Feed - June 22, 2016 Category: Consumer Health News Tags: Neurology Mental health Diabetes Source Type: news
Calling All Researchers: Submit Your Grant Applications for the 2016 Brian D. Novis Research Awards
The Brian D. Novis Research Awards honor the IMF's founder Brian Novis, who died of multiple myeloma in July of 1992. The awards go to researchers doing work in the field of multiple myeloma and related disorders including smoldering myeloma, MGUS (monoclonal gammopathy of undetermined significance), as well as immunoglobulin-derived amyloidosis. The 2016 awards are $50,000 each for junior grants and $80,000 for senior grants. August 1, 2016 is the deadline for applications. For more information and grant applications, click HERE. (Source: International Myeloma Foundation)
Source: International Myeloma Foundation - May 27, 2016 Category: Hematology Source Type: news
Amyloidosis
Title: AmyloidosisCategory: Diseases and ConditionsCreated: 12/31/1997 12:00:00 AMLast Editorial Review: 5/19/2016 12:00:00 AM (Source: MedicineNet Arthritis General)
Source: MedicineNet Arthritis General - May 19, 2016 Category: Rheumatology Source Type: news
Sylvester researchers develop novel disease model to study multiple myeloma
(University of Miami Miller School of Medicine) Researchers at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine have developed an animal model that allows them to better understand the mechanisms that lead to the development of multiple myeloma, a hematologic cancer of plasma cells, and the amyloidosis that sometimes accompanies it. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - May 5, 2016 Category: Biology Source Type: news
Protein trigger for juvenile idiopathic arthritis identified
US scientists have successfully identified a protein that plays a potentially key role in triggering juvenile idiopathic arthritis.Scientists at the Albert Einstein College of Medicine in New York have identified a human protein called transthyretin (TTR) that causes an autoimmune reaction in the joints of youngsters with this form of the disease - a discovery that could pave the way for new treatment options.The role of the TTR protein Juvenile idiopathic arthritis is the most common form of childhood arthritis and is understood to be an autoimmune disease, caused by antibodies attacking certain proteins in a person's...
Source: Arthritis Research UK - February 29, 2016 Category: Rheumatology Source Type: news
Leading efforts to better understand amyloidosis diseases
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The Catalyst welcomes guest contributors, including patients, stakeholders, innovators and others, to share their perspectives and point of view. Views represented here may not be those of PhRMA, though they are no less key to a healthy dialogue on issues in health care today.
We’re pleased to host a guest blog from Isabelle Lousada, president and CEO of the Amyloidosis Research Consortium. (Source: The Catalyst)
Source: The Catalyst - February 26, 2016 Category: Pharmaceuticals Authors: Guest Contributor Tags: Rare Diseases & Rare Disease Day Source Type: news
Karmanos ’ Myeloma and Amyloidosis team receives prestigious award for contributions to multiple myeloma research
(Source: Karmanos Cancer Institute)
Source: Karmanos Cancer Institute - February 19, 2016 Category: Cancer & Oncology Source Type: news
Karmanos’ Myeloma and Amyloidosis team receives prestigious award for contributions to multiple myeloma research
(Source: Karmanos Cancer Institute)
Source: Karmanos Cancer Institute - February 19, 2016 Category: Cancer & Oncology Source Type: news
Astrocytes implicated in preclinical AD
Astrocytes are activated in the brains of people with autosomal dominant Alzheimer’s disease long before symptoms appear and even before amyloidosis begins, a study shows. (Source: MedWire News)
Source: MedWire News - February 13, 2016 Category: Consumer Health News Tags: Alzheimer ' s disease Source Type: news
Discovery: Molecular mechanism at root of familial amyloidosis and other diseases
A team of local researchers has proposed a molecular mechanism that may be responsible for the development of life-threatening diseases called amyloidoses. (Source: Parkinson's Disease News From Medical News Today)
Source: Parkinson's Disease News From Medical News Today - November 13, 2015 Category: Neurology Tags: Alzheimer's / Dementia Source Type: news
Molecular mechanism at root of familial amyloidosis and other diseases
A team of local researchers has proposed a molecular mechanism that may be responsible for the development of life-threatening diseases called amyloidoses. The best known of such diseases is Alzheimer's disease, but there are many others that are receiving increased scrutiny, in part because of mounting evidence linking them to atherosclerosis and aging. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - November 12, 2015 Category: Science Source Type: news
Predicting Progressive Atrophy in Mild Cognitive ImpairmentPredicting Progressive Atrophy in Mild Cognitive Impairment
Dr Barclay reviews a study aiming to determine how beta-amyloidosis and neurodegeneration predict regional progression of hypometabolism and atrophy in patients with mild cognitive impairment. Medscape Neurology (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - November 5, 2015 Category: Neurology Tags: Neurology & Neurosurgery Viewpoint Source Type: news
Prothena to Initiate PRONTO, a Global Trial of NEOD001 in Patients With AL Amyloidosis With Primary Endpoint of Cardiac Response
(Source: Medical News (via PRIMEZONE))
Source: Medical News (via PRIMEZONE) - October 15, 2015 Category: Pharmaceuticals Source Type: news
High dose chemo & stem cell transplantation results in long-term survival for amyloid patients
(Boston University Medical Center) Patients with Light-chain amyloidosis who are treated with high-dose chemotherapy and autologous (one's own) stem cell transplantation (HDM/SCT) have the greatest success for long-term survival. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 8, 2015 Category: Cancer & Oncology Source Type: news
Light Chain Amyloidosis No Systemic Threat (CME/CE)
(MedPage Today) -- Thorough initial evaluation, long-term follow-up essential (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - September 25, 2015 Category: Hematology Source Type: news
